Key Points
- CFO Quan Anh Vu acquired 1,500 shares on December 26 at an average price of $69.95 for a total of $104,925, a transaction disclosed in an SEC filing that brings his direct ownership to 1,500 shares.
- Shares opened at $65.57 and were trading down 4.7%; the company has a market capitalization of about $438 million, a negative P/E, a 12‑month range of $21–$105, and an average analyst rating of Buy with a $106.20 price target.
- Monopar is a clinical-stage biotech focused on a pretargeted radioimmunotherapy (PRIT) platform, and it recently reported a quarterly loss of $0.48 per share, missing estimates.
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CFO Quan Anh Vu acquired 1,500 shares of the stock in a transaction dated Friday, December 26th. The stock was acquired at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the purchase, the chief financial officer directly owned 1,500 shares in the company, valued at approximately $104,925. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.
Monopar Therapeutics Trading Down 4.7%
Shares of NASDAQ MNPR opened at $65.57 on Tuesday. Monopar Therapeutics Inc. has a 12-month low of $21.00 and a 12-month high of $105.00. The firm has a market capitalization of $438.01 million, a price-to-earnings ratio of -19.06 and a beta of 1.46. The firm has a 50 day moving average of $79.24 and a 200 day moving average of $60.49.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Sell-side analysts predict that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.
Institutional Investors Weigh In On Monopar Therapeutics
Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics during the third quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics in the second quarter worth $34,000. AlphaQuest LLC purchased a new stake in Monopar Therapeutics during the first quarter valued at $44,000. BNP Paribas Financial Markets lifted its position in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have commented on MNPR shares. Lake Street Capital began coverage on Monopar Therapeutics in a research report on Tuesday, September 23rd. They issued a "buy" rating and a $106.00 price target for the company. Raymond James Financial downgraded Monopar Therapeutics from a "strong-buy" rating to an "outperform" rating and cut their price objective for the company from $142.00 to $123.00 in a research note on Friday, November 14th. Piper Sandler set a $95.00 target price on shares of Monopar Therapeutics and gave the stock an "overweight" rating in a report on Thursday, September 25th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Finally, Barclays set a $125.00 target price on shares of Monopar Therapeutics and gave the stock an "overweight" rating in a report on Monday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $106.20.
View Our Latest Analysis on MNPR
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
